RBF Capital LLC Sells 40,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

RBF Capital LLC trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 44.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,000 shares of the company's stock after selling 40,000 shares during the quarter. RBF Capital LLC's holdings in Teva Pharmaceutical Industries were worth $1,102,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. FMR LLC lifted its stake in Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the period. Todd Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $58,243,000. Marshall Wace LLP grew its holdings in Teva Pharmaceutical Industries by 87.8% during the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after acquiring an additional 2,410,420 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $38,914,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.0 %

TEVA traded down $0.01 during midday trading on Monday, hitting $14.87. 5,693,219 shares of the company's stock traded hands, compared to its average volume of 12,240,468. The stock's fifty day simple moving average is $15.23 and its 200-day simple moving average is $17.56. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company has a market cap of $16.85 billion, a PE ratio of -10.25, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of research analyst reports. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Finally, Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.